For investors
The case for DuraRad.
A large, fast-consolidating market with a hard infrastructure bottleneck, a drop-in container-closure business model, and a founder who has run CMC at the level this needs. Here is the opportunity, the model, and the plan.
The demand driver
A proven market with a stability bottleneck.
Radioligand therapy is already approved, growing fast, and consolidating into big pharma. What keeps limiting it is not the science but the logistics: doses decay and degrade before they reach patients. DuraRad sells into that bottleneck.
$15–22B
Projected radiopharmaceutical market by the early-to-mid 2030s
from ~$6–8B mid-2020s; third-party analyst range
~$14B
Radiopharma acquisitions by four of the largest drugmakers in about six years
Novartis, Lilly, BMS, AstraZeneca
~$2B
Pluvicto full-year 2025 sales, up about 42 percent
nuclear medicine’s first blockbuster (Novartis FY2025)
Market-size figures are third-party analyst projections; base years, scope, and methodology differ by firm, so estimates vary. Deal values are as announced. See the full context and sources on the field.
The business model
How DuraRad reaches the market.
DuraRad is priced to travel with the vial, not to replace the drug. The direction below is pre-commercial: it frames how the coating is intended to be adopted and monetized, not a signed commercial term.
A drop-in container-closure component
DuraRad is a coating on the inside of the vial wall, not a reformulation and not a device. It is applied upstream, at the vial maker or CDMO, and designed to be supplied as a sterile, ready-to-use container, so the vial arrives ready to fill and adopting it does not ask a drug owner to change the drug.
Licensed, priced as a per-vial premium or royalty
The intended model is to license the coating to vial makers and CDMOs and to capture value as a per-vial premium or royalty on coated primary packaging, rather than manufacturing and selling vials ourselves. Revenue scales with partners’ volume instead of our own capacity. The revenue base is therefore not drug sales but coated vials. Radioligand therapy is filled and shipped in a vial, and DuraRad is intended to be priced per vial, so the volume that matters is therapeutic vials filled per year, not the value of the drug inside them. The vial-volume build-up and royalty assumptions are in the DuraRad data package.
Beachhead, then platform
The wedge is the Lu-177 therapeutic vial, where the commercial volume and the stability pain are both largest. The same container-closure approach extends across the isotope roster from there.
Why it holds
The coating adds margin alongside the chemical stabilizers a dose already carries rather than replacing them, so it strengthens a formulation a sponsor has already qualified instead of asking for a new one. What is hard to replicate is the immobilization chemistry, the filed provisional applications, and the coating production process, which is held as trade secret. Confidentiality agreements are in place with clinical-stage radiopharmaceutical developers and with primary-packaging and equipment manufacturers, and a material transfer agreement is in legal review.
Why a container-closure component fits, the regulatory framing that follows from it, and why a dose that already carries stabilizers has room for more oxidative-stability margin.
The plan
The step from proof of concept to a pilot line.
FabUTech is a pre-Series-A company with a completed cold-bench proof of concept and the radioactive validation readout ahead. That study is already funded, designed and scheduled for Q4 2026; it does not depend on what comes next. The next stage turns a working, measured coating into a repeatable, partner-ready one.
The detailed model, the financials, and the operating plan behind it are shared under NDA as part of the DuraRad data package.
- What comes next
-
Process scale-up with a CMO
Move the coating from a manual, hand-made process to a partner-run, repeatable one.
-
A development lab and evaluation-kit pilot line
Stand up a small commercial-development lab and pilot line to produce evaluation kits at consistent quality and begin the transition toward commercial supply.
-
Two scientist hires
Add full-time technical depth alongside the founder, the fractional CFO, and the advisory board.
-
FDA classification feedback
Carry the submitted pre-RFD through FDA’s Office of Combination Products to the agency’s early read on classification.
-
International (PCT) filing
Convert the filed provisional applications into a PCT filing to hold the international position.
Why now
The core function is measured. The hot readout is Q4 2026.
The coating’s peroxide clearance is measured on the cold bench, the study that converts modeled to proven is designed and scheduled, and the operator has done this before.
Measured, not just modeled
The coating’s peroxide-clearance rate is measured on the cold bench at k = 0.107 per minute. Every modeled performance figure on the site is built from that measured input.
See the evidence →The de-risking readout is next
The radioactive validation study, run in Dr. Daniel Thorek’s lab at Washington University’s Mallinckrodt Institute of Radiology, is funded, designed and scheduled for Q4 2026 and turns the model’s one open assumption into a measured result.
See the study →Built by the right operator
Founded by a biologics and radiopharmaceutical CMC leader who contributed to three FDA-approved biologics and led CMC on a Zr-89-radiolabeled monoclonal antibody BLA.
Meet the company →Run the diligence.
A conversation comes first. From there, the DuraRad data package carries the measured proof-of-concept data, the modeled projections, and the detail appropriate to diligence.
Important notes
DuraRad is investigational and not approved for clinical use. Every quantitative performance figure on this site is modeled or a measured cold-bench result; no in-vial performance under live irradiation has yet been validated. The value-capture model described here is directional and pre-commercial. Market projections are third-party analyst estimates. Statements about the plan and future milestones are forward-looking, describe current intentions, and are not offers to sell or solicitations to buy any security. Nothing on this page is an offer of securities. Any investment discussion proceeds under appropriate agreements.